|Bid||225.53 x 800|
|Ask||226.68 x 800|
|Day's Range||221.53 - 227.80|
|52 Week Range||216.12 - 388.67|
|Beta (3Y Monthly)||1.85|
|PE Ratio (TTM)||10.49|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Adults with later-onset spinal muscular atrophy (SMA) who are not being treated show increased rates of hospital admissions, clinical interventions and mortality, indicating an.
NEW YORK, March 26, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Biogen (BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia. “This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience. We are incredibly grateful to all the Alzheimer’s disease patients, their families and the investigators who participated in the trials and contributed greatly to this research,” said Michel Vounatsos, Chief Executive Officer at Biogen.
Biogen (BIIB) today announced that it has entered into a share purchase agreement with FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire the shares of Biogen’s subsidiary, which holds Biogen’s biologics manufacturing operations in Hillerød, Denmark, for up to $890 million in cash, subject to minimum purchase commitment guarantees and other contractual terms.
Biogen to acquire Nightstar Therapeutics for $25.50 per share Nightstar Therapeutics is a gene therapy company focused on developing novel treatments for patients suffering.
Today, CADTH publicly released updated recommendations that could inform provincial jurisdictions’ decisions on the public reimbursement of SPINRAZA (nusinersen), the first and only approved treatment shown to be effective in the treatment of Spinal Muscular Atrophy (SMA).
Biogen Inc. (BIIB) today announced that SPINRAZA (nusinersen) has been approved by the China National Medical Products Association (NMPA) for the treatment of 5q spinal muscular atrophy (SMA), expanding the company’s presence in China. Approximately 95 percent of all SMA cases are 5q SMA, making it the most common form of the disease.
NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Alkermes plc (ALKS) and Biogen Inc. (BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for diroximel fumarate (BIIB098), a novel oral fumarate in development for the treatment of relapsing forms of multiple sclerosis (MS). The NDA has been assigned a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019. If approved, Biogen intends to market diroximel fumarate under the brand name VUMERITY™, which has been conditionally accepted by the FDA and will be confirmed upon approval.
CAMBRIDGE, Mass. and WALTHAM, Mass., Jan. 4, 2019 /PRNewswire/ -- Biogen Inc (BIIB) and Skyhawk Therapeutics, Inc. (Skyhawk) today announced a strategic collaboration in which the companies will leverage Skyhawk's SkySTAR™ technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases. Biogen will have the option to license therapies resulting from the collaboration and will be responsible for their development and potential commercialization.
Biogen Inc (BIIB) and C4 Therapeutics (C4T) announced today that they have entered into a strategic collaboration to investigate the use of C4T’s novel protein degradation platform to discover and develop potential new treatments for neurological conditions, such as Alzheimer’s disease and Parkinson’s disease. Under the agreement, C4T will provide expertise and research services in targeted protein degradation and Biogen will provide neuroscience expertise and drug development capabilities.
Currently commercialized under the brand name TYSABRI®, natalizumab 300 mg dosed every four weeks is the only approved dosing regimen. Patients who switch to EID after one year of treatment with natalizumab SID will be evaluated in relation to patients receiving continued SID treatment. “For more than a decade, natalizumab has been considered a highly effective treatment option for patients with relapsing forms of MS,” said Alfred Sandrock, Jr., M.D., Ph.D., executive vice president and chief medical officer at Biogen.
Biogen Canada applauds the Government of Quebec’s decision to cover SPINRAZA for a broad population of patients with Spinal Muscular Atrophy (SMA) in the province. The announcement was made by the Minister of Health, Madame Danielle McCann on December 18, 2018, following a positive recommendation from the Institut national d'excellence en santé et services sociaux (INESSS) to expand coverage to include pre-symptomatic and symptomatic patients with 5q SMA Type 1, 2 and 3 of all ages.
NEW YORK, NY / ACCESSWIRE / December 19, 2018 / Shares of Biogen were continuing to slump on Tuesday after a slight recovery on Monday from last week’s descent. The company and Alkermes plc recently announced that Alkermes has submitted a New Drug Application to the FDA for diroximel fumarate (BIIB098). Shares of Biocept were soaring on high volume on news that the company has entered into a Software License and Laboratory Data Supply Agreement with Prognos, Inc.
Alkermes plc (ALKS) and Biogen Inc. (BIIB) today announced that Alkermes has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for diroximel fumarate (BIIB098), a novel oral fumarate in development for the treatment of relapsing forms of multiple sclerosis (MS). Alkermes is seeking approval of diroximel fumarate under the 505(b)(2) regulatory pathway, and the NDA submission includes data from EVOLVE-1, a Phase 3 pivotal trial that evaluated long-term safety in relapsing-remitting MS (RRMS) with approximately 700 patients dosed with diroximel fumarate. If approved, Biogen intends to market diroximel fumarate under the brand name VUMERITY™.
Biogen Inc (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) announced today that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1RX), an investigational treatment for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations. ALS with SOD1 mutations is a subtype of familial ALS and accounts for approximately two percent of all ALS cases.